GSK Bets $10.6 Billion on Nuvalent to Revive Oncology Pipeline

A 40% premium price tag marks GSK’s aggressive pivot into cancer research, as the British pharmaceutical giant moves to acquire U.S.-based developer Nuvalent for $10.6 billion. The all-cash deal, valued at $124 per share, represents the company's largest acquisition in over a decade under the leadership of CEO Luke Miels.

Editorial·June 9, 2026·reads: 3,436

GSK Bets $10.6 Billion on Nuvalent to Revive Oncology Pipeline

The strategy signals a departure from smaller, incremental purchases, aiming to secure a competitive foothold against industry rival AstraZeneca. By integrating Nuvalent’s specialized lung cancer treatments, GSK seeks to bolster its late-stage experimental portfolio and mitigate risks associated with looming patent expirations.

Investors responded swiftly to the announcement, pushing Nuvalent shares up 38% in premarket trading, while GSK saw a marginal decline in London. For Miels, the acquisition is a cornerstone of a broader roadmap designed to hit £40 billion in annual revenue by 2031. The merger is expected to transform GSK’s oncology division into a primary engine for growth as the firm shifts its long-term research focus toward more lucrative, high-stakes cancer therapies.